European Code Against Cancer and scientific justification: third version (2003)
Open Access
- 1 July 2003
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 14 (7), 973-1005
- https://doi.org/10.1093/annonc/mdg305
Abstract
Received 28 April 2003; accepted 7 May 2003Keywords
This publication has 31 references indexed in Scilit:
- Overview of the main outcomes in breast-cancer prevention trialsThe Lancet, 2003
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised womenThe Lancet, 1998
- Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trialThe Lancet, 1998
- Effects of a Combination of Beta Carotene and Vitamin A on Lung Cancer and Cardiovascular DiseaseNew England Journal of Medicine, 1996
- European School of Oncology Advisory report to the European Commission for the “Europe Against Cancer Programme” European Code Against CancerEuropean Journal Of Cancer, 1995
- Effect of sulindac on sporadic colonic polypsGastroenterology, 1995
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Improving prognosis of Hodgkin's disease in ScotlandEuropean Journal of Cancer and Clinical Oncology, 1988
- A mathematical model for the age distribution of cancer in manInternational Journal of Cancer, 1969